Meeting
2017 ASCO Annual Meeting
A phase I study of the tolerability, safety, pharmacokinetics and preliminary antitumor effects of KBP-5209, a novel pan-HER inhibitor, in patients with advanced solid tumors.
Authors
Sarina Anne Piha-Paul
The University of Texas MD Anderson Cancer Center, Houston, TX
Sarina Anne Piha-Paul , Sunil Sharma , Chengkon Shih , Bert H. O'Neil , Qinghong Zhou , Yuli Ding , Na Ou , Tingting Yu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Pharmacology
Clinical Trial Registration Number
NCT02442414
Citation
J Clin Oncol 35, 2017 (suppl; abstr 2565)
DOI
10.1200/JCO.2017.35.15_suppl.2565
Abstract #
2565
Poster Bd #
57
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Masterkey-01: Phase I/II, open-label multicenter study to assess safety, tolerability, pharmacokinetics, and antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies.
First Author: Erika Paige Hamilton
Poster
2017 ASCO Annual Meeting
Phase I study to evaluate the tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) of PM01183 (Lurbinectedin) in combination with olaparib in patients with advanced solid tumors.
First Author: Andres Poveda
Poster
2011 ASCO Annual Meeting
Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors.
First Author: M. Simonelli
First Author: J. Thaddeus Thaddeus Beck